Business Description
Protagenic Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US74365N2027
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.77 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -7.9 | |||||
3-Year EPS without NRI Growth Rate | 2.8 | |||||
3-Year FCF Growth Rate | -19.3 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 22.93 | |||||
9-Day RSI | 35.65 | |||||
14-Day RSI | 41.53 | |||||
6-1 Month Momentum % | 77.71 | |||||
12-1 Month Momentum % | -32.57 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.53 | |||||
Quick Ratio | 5.53 | |||||
Cash Ratio | 5.43 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.6 | |||||
Shareholder Yield % | -1.4 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -137.9 | |||||
ROA % | -111.57 | |||||
ROIC % | -1873.22 | |||||
ROC (Joel Greenblatt) % | -10085.03 | |||||
ROCE % | -136.12 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.54 | |||||
Price-to-Tangible-Book | 2.52 | |||||
EV-to-EBIT | -0.09 | |||||
EV-to-EBITDA | -0.09 | |||||
EV-to-FCF | -0.11 | |||||
Price-to-Net-Current-Asset-Value | 2.64 | |||||
Price-to-Net-Cash | 2.71 | |||||
Earnings Yield (Greenblatt) % | -1111.11 | |||||
FCF Yield % | -92.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Protagenic Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.265 | ||
Beta | 1.61 | ||
Volatility % | 97.28 | ||
14-Day RSI | 41.53 | ||
14-Day ATR (€) | 0.068911 | ||
20-Day SMA (€) | 1.2305 | ||
12-1 Month Momentum % | -32.57 | ||
52-Week Range (€) | 0.638 - 1.94 | ||
Shares Outstanding (Mil) | 4.44 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Protagenic Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Protagenic Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Protagenic Therapeutics Inc Frequently Asked Questions
What is Protagenic Therapeutics Inc(STU:MBP)'s stock price today?
When is next earnings date of Protagenic Therapeutics Inc(STU:MBP)?
Does Protagenic Therapeutics Inc(STU:MBP) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |